Man with diabetes reaching his A1C goal with Xultophy® 100/3.6 Man with diabetes reaching his A1C goal with Xultophy® 100/3.6 Man with diabetes reaching his A1C goal with Xultophy® 100/3.6

Xultophy® 100/3.6  & A1C

Reaching an A1C of less than 7% is a goal shared by many people with type 2 diabetes. See how Xultophy® 100/3.6 performed in clinical studies.

Xultophy® 100/3.6 is clinically proven to significantly lower A1C

Xultophy® 100/3.6 lowered A1C in people switching from Lantus®

Across all clinical studies, Xultophy® 100/3.6 helped the majority of people reach an average A1C of less than 7%, the American Diabetes Association (ADA) goal.c,d

Across all clinical studies, Xultophy® 100/3.6 helped lower A1C
The percentage of people who reached the ADA A1C goal across 3 clinical studies for Xultophy® 100/3.6 ranged from 57.3% to 74.6%.
aStudy C compared Xultophy® 100/3.6 with the leading long-acting insulin, Lantus®. Those taking Lantus® lowered their A1C an average 1.16% points (from 8.2 to 7.1), while those switching to Xultophy® 100/3.6 dropped 1.67% points.
bAverage doses at the end of the study were 41 units of Xultophy® 100/3.6 and 66 units of Lantus®. The clinical importance of this difference is uncertain. Doses could not be increased by more than 4 units per week and there was no maximum dose of Lantus®. A1C results may not reflect those seen outside a clinical study, where different doses of Lantus® can be used.
cIndividual results may vary from results in clinical studies.
dThree 26-week, head-to-head studies were done involving more than 1300 people with type 2 diabetes.
eStudy B compared Xultophy® 100/3.6 with a long-acting insulin. Those taking long-acting insulin lowered their A1C an average 1.05% points (from 8.8 to 7.7), while those switching to Xultophy® 100/3.6 dropped 1.94% points. End-of-study doses of both medicines was 46 units.
fStudy A compared Xultophy® 100/3.6 with a medicine called liraglutide. Those taking unchanged liraglutide lowered their A1C an average 0.36% points (from 7.8 to 7.4), while those switching to Xultophy® 100/3.6 dropped 1.31% points. The end-of-study dose of Xultophy® 100/3.6 was 44 units.
Xultophy® 100/3.6 Savings Card

Save on Xultophy® 100/3.6

Sign up for the Xultophy® 100/3.6 Savings Card and, if eligible, pay as little as $1 per day on plans that cover Xultophy® 100/3.6. For commercially insured patients only. Maximum monthly savings of $400, up to 12 months. Eligibility and other restrictions apply.

Sign up for a card

Woman preparing to talk with her doctor about Xultophy® 100/3.6 Woman preparing to talk with her doctor about Xultophy® 100/3.6 Woman preparing to talk with her doctor about Xultophy® 100/3.6
Woman preparing to talk with her doctor about Xultophy® 100/3.6

We've compiled some questions to help guide the conversation with your health care provider at your next appointment.

Get questions for your doctor